Cargando…

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility

Background: Drug incompatibility is defined as a physical-chemical reaction between two or more injectable drugs and that results mainly in precipitation or insolubility. Several strategies for reducing incompatibilities have been implemented empirically in intensive care units. However, these strat...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin Mena, Anthony, Négrier, Laura, Treizebré, Anthony, Guilbert, Marie, Bonnaire, Lucille, Daniau, Valentine, Leba Bonki, Gabie, Odou, Pascal, Genay, Stéphanie, Décaudin, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459903/
https://www.ncbi.nlm.nih.gov/pubmed/37631283
http://dx.doi.org/10.3390/pharmaceutics15082069
_version_ 1785097523586662400
author Martin Mena, Anthony
Négrier, Laura
Treizebré, Anthony
Guilbert, Marie
Bonnaire, Lucille
Daniau, Valentine
Leba Bonki, Gabie
Odou, Pascal
Genay, Stéphanie
Décaudin, Bertrand
author_facet Martin Mena, Anthony
Négrier, Laura
Treizebré, Anthony
Guilbert, Marie
Bonnaire, Lucille
Daniau, Valentine
Leba Bonki, Gabie
Odou, Pascal
Genay, Stéphanie
Décaudin, Bertrand
author_sort Martin Mena, Anthony
collection PubMed
description Background: Drug incompatibility is defined as a physical-chemical reaction between two or more injectable drugs and that results mainly in precipitation or insolubility. Several strategies for reducing incompatibilities have been implemented empirically in intensive care units. However, these strategies have never been compared directly (and particularly in terms of the particulate load and drug mass flow rate) under standardized conditions. The objective of the present in vitro study was to evaluate the impact of various strategies for preventing incompatibility between simultaneously infused vancomycin and piperacillin/tazobactam. Methods: An in-line filter, a dilute vancomycin solution (5 mg/mL), and an alternative saline administration line were evaluated separately. The infusion line outlet was connected to a dynamic particle counter. The antibiotic concentration was measured in an HPLC-UV assay. Result: The use of an in-line filter and an alternative saline administration route did not significantly reduce the particulate load caused by vancomycin-piperacillin/tazobactam incompatibility. Dilution of the vancomycin solution was associated with a significantly lower particulate load and maintenance of the vancomycin mass flow rate. Discussion: It is important to systematically compare the efficacy of strategies for preventing drug incompatibility. The use of diluted vancomycin solution gave the best results in the case of vancomycin-piperacillin/tazobactam incompatibility.
format Online
Article
Text
id pubmed-10459903
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104599032023-08-27 Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility Martin Mena, Anthony Négrier, Laura Treizebré, Anthony Guilbert, Marie Bonnaire, Lucille Daniau, Valentine Leba Bonki, Gabie Odou, Pascal Genay, Stéphanie Décaudin, Bertrand Pharmaceutics Article Background: Drug incompatibility is defined as a physical-chemical reaction between two or more injectable drugs and that results mainly in precipitation or insolubility. Several strategies for reducing incompatibilities have been implemented empirically in intensive care units. However, these strategies have never been compared directly (and particularly in terms of the particulate load and drug mass flow rate) under standardized conditions. The objective of the present in vitro study was to evaluate the impact of various strategies for preventing incompatibility between simultaneously infused vancomycin and piperacillin/tazobactam. Methods: An in-line filter, a dilute vancomycin solution (5 mg/mL), and an alternative saline administration line were evaluated separately. The infusion line outlet was connected to a dynamic particle counter. The antibiotic concentration was measured in an HPLC-UV assay. Result: The use of an in-line filter and an alternative saline administration route did not significantly reduce the particulate load caused by vancomycin-piperacillin/tazobactam incompatibility. Dilution of the vancomycin solution was associated with a significantly lower particulate load and maintenance of the vancomycin mass flow rate. Discussion: It is important to systematically compare the efficacy of strategies for preventing drug incompatibility. The use of diluted vancomycin solution gave the best results in the case of vancomycin-piperacillin/tazobactam incompatibility. MDPI 2023-08-01 /pmc/articles/PMC10459903/ /pubmed/37631283 http://dx.doi.org/10.3390/pharmaceutics15082069 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Martin Mena, Anthony
Négrier, Laura
Treizebré, Anthony
Guilbert, Marie
Bonnaire, Lucille
Daniau, Valentine
Leba Bonki, Gabie
Odou, Pascal
Genay, Stéphanie
Décaudin, Bertrand
Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
title Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
title_full Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
title_fullStr Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
title_full_unstemmed Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
title_short Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
title_sort evaluation of strategies for reducing vancomycin-piperacillin/tazobactam incompatibility
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459903/
https://www.ncbi.nlm.nih.gov/pubmed/37631283
http://dx.doi.org/10.3390/pharmaceutics15082069
work_keys_str_mv AT martinmenaanthony evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility
AT negrierlaura evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility
AT treizebreanthony evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility
AT guilbertmarie evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility
AT bonnairelucille evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility
AT daniauvalentine evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility
AT lebabonkigabie evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility
AT odoupascal evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility
AT genaystephanie evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility
AT decaudinbertrand evaluationofstrategiesforreducingvancomycinpiperacillintazobactamincompatibility